Mould, Mycotoxins, and Chronic Illness: The Hidden Environmental Threat

The Biology of Mould: More Than a Nuisance

Mould is ancient. Fungi have been on this planet for over a billion years, and in evolutionary terms, they are far more closely related to animals than to plants. In the built environment, the moulds that matter most for human health belong to genera including Stachybotrys (often called black mould), Aspergillus, Penicillium, Chaetomium, and Fusarium. These organisms do not simply sit passively in a damp corner. They are chemically aggressive, producing hundreds of secondary metabolites that function as weapons against competing microorganisms and environmental threats.

The compounds that matter most for human illness are mycotoxins: small, lipophilic molecules that penetrate biological membranes with ease. Trichothecenes, produced by Stachybotrys chartarum (the notorious black mould) and several Fusarium species, inhibit protein synthesis at the ribosomal level. They are so potent that trichothecene weaponization has been explored in biological warfare programs. Ochratoxin A, produced by Aspergillus and Penicillium species common in water-damaged buildings, is nephrotoxic and immunosuppressive. Aflatoxins, from Aspergillus flavus and Aspergillus parasiticus, are among the most potent naturally occurring carcinogens known. Gliotoxin, from Aspergillus fumigatus, suppresses the innate immune system and promotes fungal colonization of the respiratory tract.

What makes water-damaged buildings particularly toxic is that mould is rarely the only biological threat. The complex ecology of a wet building wall includes bacteria (particularly gram-negative organisms releasing lipopolysaccharide endotoxins), actinomycetes, and the volatile organic compounds produced by both fungi and bacteria during decomposition of building materials. This toxic soup, which researchers call the biotoxin mixture of water-damaged buildings, is more injurious than any single component studied in isolation.

Estimates from the EPA and independent researchers suggest that between 25% and 50% of buildings in the United States have moisture problems significant enough to support mould growth. In countries with colder climates, older housing stock, or frequent flooding, the proportions are similar or higher. The problem is vast, it is largely invisible (most mould grows inside walls, in ceiling voids, and in HVAC systems), and its health consequences are only beginning to be quantified at the population level.

How Mycotoxins Enter the Body and What They Do

The primary route of mycotoxin exposure in water-damaged buildings is inhalation of mycotoxin-laden spore fragments and dust particles. However, dermal absorption through skin contact with contaminated surfaces and ingestion through settled dust on hands and food are also significant routes. Once inhaled, mycotoxins are absorbed rapidly across the respiratory epithelium, which offers little barrier function for lipophilic molecules. From the lungs, they enter the systemic circulation within minutes.

Once in the body, mycotoxins distribute widely to target organs. Many show particular affinity for the liver (where biotransformation is attempted), the kidneys, the brain, and reproductive tissues. At the cellular level, their primary mechanisms of damage include: disruption of mitochondrial electron transport chain function and ATP production; induction of oxidative stress through depletion of glutathione and generation of reactive oxygen species; direct damage to DNA; activation of the NF-kB inflammatory signaling pathway; and interference with cytokine regulation.

For the majority of people (roughly 76% of the population, according to Dr. Ritchie Shoemaker), the immune system can recognize and begin to clear biotoxins through antibody formation and normal biotransformation pathways. These individuals may feel temporarily unwell in a mouldy environment but recover when they leave. For the remaining 24%, the story is very different.

As documented in research on indoor air quality and cognitive function, the air quality within buildings has profound effects on brain performance, and nowhere is this clearer than in the neurological symptoms of mould-exposed individuals, which include brain fog, memory impairment, word-finding difficulties, and measurable reductions in cognitive test performance.

CIRS: The Genetics of Vulnerability

Chronic Inflammatory Response Syndrome (CIRS) is the condition that develops in genetically susceptible individuals following exposure to water-damaged buildings. The genetic basis lies in the HLA-DR system, a family of genes on chromosome 6 that encodes the proteins responsible for presenting antigens to the adaptive immune system. Specific HLA-DR haplotypes (inherited combinations of variants) determine whether a person can mount an effective antibody response to biotoxins.

Approximately 24% of the population carries HLA-DR variants that impair this antigen presentation for mould biotoxins. Their immune systems cannot form antibodies against these toxins, meaning the body cannot tag them for removal through normal pathways. Instead, the biotoxins recirculate indefinitely, continuing to stimulate the innate immune system and driving chronic inflammatory cytokine production. The result is a self-perpetuating inflammatory state that continues even after the person leaves the contaminated environment, as long as their toxic body burden remains high.

Dr. Ritchie Shoemaker, a Maryland physician and researcher who has treated thousands of CIRS patients since the late 1990s, mapped the downstream consequences of this immune dysfunction with remarkable specificity. Chronically elevated inflammatory cytokines (particularly TGF-beta 1, C4a complement, and MMP-9) suppress the production of melanocyte-stimulating hormone (MSH) in the hypothalamus. MSH normally regulates inflammation, maintains the intestinal mucosal barrier, controls the release of pituitary hormones, and regulates pain and sleep cycles. Its depletion cascades into a multi-system hormonal collapse.

With MSH suppressed, anti-diuretic hormone (ADH) dysregulation causes excessive thirst and frequent urination. ACTH dysregulation leads to cortisol abnormalities. Vasoactive intestinal peptide (VIP) suppression impairs pulmonary blood flow regulation and causes post-exertional malaise. The net result is a patient presenting with fatigue, cognitive impairment, muscle pain, sleep disturbance, mood disorders, hormonal dysfunction, and a bewildering range of seemingly unconnected symptoms that rarely point to a single diagnosis. This presentation is regularly mischaracterized as fibromyalgia, chronic fatigue syndrome, depression, anxiety, or hypochondria.

The Neurological Dimension: Brain Inflammation and Structural Changes

One of the most striking and clinically important findings in CIRS research is the demonstration of measurable structural brain changes in affected individuals. Using NeuroQuant MRI software, which automatically quantifies grey matter volumes in specific brain regions, researchers including Shoemaker and Dr. James Ryan have documented characteristic patterns of grey matter loss in CIRS patients compared to age-matched controls.

The regions affected include the caudate nucleus, putamen, and globus pallidus (involved in motor control and procedural learning), the forebrain parenchyma, the cortical grey matter, and critically, the limbic structures involved in memory and emotional regulation. The pattern is not random: it reflects the distribution of cytokine-mediated neuroinflammation and the sensitivity of specific brain regions to inflammatory damage.

Equally remarkable is that these structural changes appear to be at least partially reversible with appropriate treatment. Follow-up NeuroQuant studies in treated patients show measurable recovery of grey matter volumes in many regions, particularly the forebrain, correlating with clinical improvement. This represents some of the most concrete evidence that CIRS is a real, biologically measurable condition rather than a functional or psychosomatic one.

The cognitive symptoms reported by CIRS patients, including profound brain fog, impaired working memory, difficulty with executive function, and emotional dysregulation, align with the structural findings. Neuropsychological testing consistently demonstrates measurable performance deficits that match the brain regions affected by the inflammatory process. These are not subjective complaints but objectively quantifiable impairments.

Symptoms, Misdiagnosis, and the Patient Journey

CIRS presents with a cluster of symptoms so diverse that it systematically defeats the organ-system approach of conventional medicine. Patients typically present with some combination of fatigue, weakness, post-exertional malaise, cognitive impairment, headaches, light sensitivity, joint pain, muscle cramping, unusual thirst and frequent urination, shortness of breath without exertion, numbness or tingling, vertigo, skin sensitivity, temperature dysregulation, and mood disturbance including anxiety and depression.

The diversity of this symptom cluster sends patients on an odyssey through medical specialties. A cardiologist evaluates the shortness of breath and finds nothing. A rheumatologist addresses the joint pain and diagnoses fibromyalgia. A neurologist investigates the cognitive symptoms and finds no structural lesion on standard MRI. A psychiatrist addresses the mood symptoms and prescribes antidepressants. Each specialist is correct within the narrow frame of their specialty, and yet the patient continues to deteriorate.

A key diagnostic tool accessible without a physician is the Visual Contrast Sensitivity (VCS) test. The retina is neurological tissue and its sensitivity to visual contrast is impaired by the same biotoxins that damage brain function. Shoemaker developed a standardized VCS test that is positive (showing impaired contrast sensitivity) in approximately 92% of CIRS patients. It can be performed online in minutes and serves as a useful screening tool and treatment monitoring instrument.

The broader picture of how environmental toxins affect cellular energy production is explored in our article on mitochondrial dysfunction and chronic disease, where we detail how impaired mitochondrial function is a central feature of many chronic illnesses including CIRS, and how restoring mitochondrial health is a key therapeutic target.

Testing, Treatment, and the Path to Recovery

Diagnosis begins with a thorough environmental and symptom history. Key questions include whether symptoms improve significantly when away from the home or workplace for extended periods (a week or more), and whether they worsen specifically in certain rooms or buildings. This pattern of building-specific symptom variation is a critical diagnostic clue that is often not explored in conventional medical history taking.

Laboratory testing in CIRS typically includes a biotoxin panel measuring C4a, TGF-beta 1, MMP-9, VEGF, MSH, VIP, ACTH, cortisol, and osmolality alongside ADH measurement. HLA-DR genotyping identifies genetic susceptibility. Urine mycotoxin testing using ELISA (Great Plains Laboratory, RealTime Labs) or mass spectrometry (Vibrant Wellness) can identify specific mycotoxins being excreted. Not all CIRS clinicians use urine mycotoxin testing, as sensitivity and specificity vary by laboratory and method.

Environmental assessment of the building is non-negotiable. Without removing the source of exposure, no treatment protocol will produce sustained recovery. ERMI (Environmental Relative Moldiness Index) testing involves dust sampling and PCR analysis for 36 mould species. HERTSMI-2 is a simplified version focusing on the five most clinically relevant species. Air sampling by an industrial hygienist provides additional information but is less sensitive than ERMI for settled dust. A score above 2 on HERTSMI-2 is considered incompatible with CIRS recovery.

Treatment follows the Shoemaker Protocol, a stepwise approach beginning with removal from exposure and use of bile acid sequestrants (cholestyramine or welchol) to bind biotoxins in the gut and interrupt their enterohepatic recirculation. Subsequent steps address specific biomarker abnormalities: MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) in the nasal sinuses are treated with intranasal antibiotics; low MSH is addressed with intranasal VIP spray; hormonal dysregulation is addressed step by step as biomarkers normalize. The complete protocol typically takes six months to two years to complete.

Recovery is possible and well-documented in case series and clinical reports, though randomized controlled trials of the full Shoemaker Protocol remain limited. The key obstacles to recovery are ongoing exposure (often because building remediation is inadequate or the patient is repeatedly re-exposed), undiagnosed comorbidities (Lyme disease co-infection is common in susceptible individuals), and failure to address all steps of the protocol systematically. For patients who can achieve full removal from exposure and complete the protocol under appropriate medical supervision, outcomes are often dramatically positive.